

[Regimen Name](#) | [Drug Regimen](#) | [Cycle Frequency](#) | [Premedication & Supportive Measures](#) | [Dose Modifications](#) | [Adverse Effects](#) | [Interactions](#) | [Drug Administration & Special Precautions](#) | [Clinical Monitoring](#) | [Administrative Information](#) | [Key References](#) | [Other Notes](#)

A	REGIMEN NAME	
	MITOMYCIN-IFOSFAMIDE-CISPLATIN Chemotherapy	
Cancer	Advanced Non-Small Cell Lung Cancer	Palliative Intent
EXCLUDED/ARCHIVE: a regimen which is no longer in use and is listed for reference purposes only, although the use of such a regimen may be appropriate in a situation where a standard regimen is deemed inadequate for specific clinical reasons.		

▲ [Back to Top](#)

B	DRUG REGIMEN		
IFOSFAMIDE (Round to nearest 25mg)	4000mg/ m ²	IV	Over 2 hours Day 1
MESNA (Round to nearest 50mg)	800mg/m ²	IV	1 hour prior to Ifosfamide Over 2 hours concurrent with Ifosfamide At 8 and 12 hours after Ifosfamide
CISPLATIN (Round to nearest 1mg)	25mg/m ²	IV	Days 1 to 3
ETOPOSIDE	100mg/m ²	IV	Days 1 to 3

▲ [Back to Top](#)

C	CYCLE FREQUENCY
	REPEAT EVERY 28 DAYS

▲ [Back to Top](#)

D	PREMEDICATION AND SUPPORTIVE MEASURES
	ANTIEMETIC REGIMEN: HESKETH LEVEL 5

▲ [Back to Top](#)

E**DOSE MODIFICATIONS**

Doses should be modified according to the protocol by which the patient is being treated. The following recommendations are in use at some centres.

Hematologic Toxicities

Refer to [Appendix 6](#) for general recommendations.

Renal Impairment

- | | |
|---------------------------|---|
| 1. If CrCl 10 – 50 mL/min | REDUCE Cisplatin* to 50% dose or OMIT dose and
REDUCE Etoposide to 75% dose |
| 2. If CrCl < 30 mL/min | REDUCE Ifosfamide to 75% dose |
| 3. If CrCl < 10 ml/min | REDUCE Etoposide to 50% dose, or OMIT dose
OMIT Cisplatin* dose AND
REDUCE Ifosfamide to 67% dose |

* At the discretion of the prescriber, less dose reduction may be suggested. See section E of [CISPLATIN](#) drug monograph.

Hepatic Impairment

- | | |
|---------------------------|--|
| 1. If Bilirubin 1-2 x ULN | REDUCE Etoposide to 50% dose |
| 2. If Bilirubin 2-4 x ULN | REDUCE Etoposide to 25% dose |
| 3. If Bilirubin >4 x ULN | STOP treatment with Etoposide |

The dose of Ifosfamide should be adjusted in the presence of hepatic dysfunction.

▲ [Back to Top](#)

F**ADVERSE EFFECTS**

Refer to the Ifosfamide, Mesna, Cisplatin and Etoposide drug monographs for full details of adverse effects.

Most Frequently Occuring Adverse Effects

- Nausea and vomiting
- Cystitis
- Myelosuppression
- Vesicant
- Nephrotoxicity
- Stomatitis and diarrhea
- Neurotoxicity (ototoxicity)

▲ [Back to Top](#)

G INTERACTIONS

Refer to the Ifosfamide, Mesna, Cisplatin and Etoposide drug monographs for full details.

▲ [Back to Top](#)

H DRUG ADMINISTRATION AND SPECIAL PRECAUTIONS

Refer to the Ifosfamide, Mesna, Cisplatin and Etoposide drug monographs for full details.

▲ [Back to Top](#)

I CLINICAL MONITORING

- Clinical toxicity assessment (including stomatitis, neurotoxicity, local toxicity, cystitis)
- CBC before each cycle
- Baseline and regular liver function tests
- Baseline and regular renal function tests (including electrolytes and magnesium) and urinalysis

▲ [Back to Top](#)

J ADMINISTRATIVE INFORMATION

Approximate drug costs (chemotherapy only) \$755.00 per treatment cycle

Complexity Value*

Regimen	171 per cycle
Pharmacy	50 per cycle
Chemo Nursing	121 per cycle

* Complexity value is the fixed time spent in minutes by nursing and pharmacy with respect to administration for each treatment cycle.

▲ [Back to Top](#)

K KEY REFERENCE(S)

Shepherd FA, Evans WK, Goss PE et al. Ifosfamide, Cisplatin and Etoposide (ICE) in the treatment of advanced non-small cell lung cancer. *Semin Oncol*, 1992;19 (Suppl 1): 54-58

▲ [Back to Top](#)